SynthesisBMC cancer2025
Weight gain or loss after diagnosis and survival outcomes in prostate cancer: a meta-analysis.
Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe relationship between weight changes and survival outcomes in patients with prostate cancer remains inconclusive. This meta-analysis aims to investigate the association between post-diagnosis weight changes and survival outcomes in patients with prostate cancer.
methodsWe systematically searched for articles indexed in the PubMed, Web of Science, and Embase databases until March 22, 2025. Longitudinal observational studies that examined the association between post-diagnosis weight change and prostate cancer-specific mortality (PCSM) or all-cause mortality among patients with prostate cancer were eligible for inclusion in this analysis. Weight gain and weight loss were defined as either a percentage change from baseline body weight at diagnosis or treatment start, or as an absolute change in kilograms over a specified period. Despite variations in the measured statistical heterogeneity, we employed a random-effects model for all meta-analyses to account for inherent differences in the definitions of weight change.
resultsSix studies involving 12,269 patients were included in the meta-analysis. When compared to a reference stable weight, post-diagnosis weight gain was associated with an increased risk of all-cause mortality (hazard ratio [HR] 1.23; 95% confidence interval [CI] 1.07–1.42) and PCSM (HR 1.64; 95% CI 1.30–2.07). Conversely, weight loss was linked to an increased risk of all-cause mortality (HR 1.54; 95% CI 1.20–1.97), while no significant association was found between weight loss and PCSM (HR 1.30; 95% CI 0.76–2.22). Begg’s and Egger’s tests indicated no evidence of publication bias. Subgroup analyses revealed that both weight loss (HR 1.38; 95% CI 1.07–1.79) and weight gain (HR 1.25; 95% CI 1.08–1.46) were significantly associated with all-cause mortality when the analysis was restricted to patients with non-metastatic or localized prostate cancer.
conclusionsPost-diagnosis weight gain is significantly associated with both all-cause mortality and PCSM in patients with prostate cancer, particularly in those with non-metastatic or localized disease. In contrast, weight loss is primarily linked to an increased risk of all-cause mortality but not to PCSM. However, the observational nature of our data limits our ability to draw definitive conclusions regarding causality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.